Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug Sibnayal™ in dRTA
December 20, 2021
- SibnayalTM eligible for reimbursement by the French public health insurance system
- ASMR IV: Recognition of the contribution of SibnayalTM in the treatment of dRTA
Paris, France, 20 December 2021 – 7:00 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces is has received a positive opinion from the French Transparency Commission (HAS) with its lead asset, SibnayalTM eligible for reimbursement with a Moderate Level SMR (Medical Rendered Service) and a Level IV ASMR (Medical Rendered Service Improvement), in the treatment of distal Renal Tubular Acidosis (dRTA) in adults, adolescents and children over the age of 1.